Morning Overview on MSN
Once-controversial exon-skipping drugs return as hope for Duchenne
Exon-skipping therapies for Duchenne muscular dystrophy, a class of drugs that triggered fierce regulatory debate when they ...
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA?
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer Patients with ...
Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
A new study describes the structure of a crucial enzyme present in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus responsible for coronavirus disease 2019 ...
There are promising developments in the pipeline for EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), and groups like The Exon 20 Group can help ensure patients are getting access ...
The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said.
A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results